Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 inhibitor, NB-4746. This first-in-class, oral, brain-penetrating inhibitor offers broad therapeutic potential across a range of neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), and […]